Two of America’s leading medical and pharmaceutical researchers, Chicago Clinical Research Institute, Inc. (CCRII) and Regeneron, have made highly positive findings in their recent clinical trial of a new SARS-CoV-2 prophylaxis. Go to https://ccrii.us to find out more.
SARS-CoV-2 Top-Enroller Trial Phase 3: Chicago's CCRII Enrolls 300+ Patients
SARS-CoV-2 Top-Enroller Trial Phase 3: Chicago's CCRII Enrolls 300+ Patients, updated 11/9/22, 6:16 AM